<?xml version="1.0" encoding="UTF-8"?>
<p>Additional assays demonstrated that chloroquine functioned at both entries and post-entry stages of the 2019-nCoV infection in Vero E6 cells. The 
 <italic>in vitro</italic> study findings revealed that remdesivir and chloroquine are highly effective in the control of COVID-19. Because these compounds have already passed the safety test against various diseases, they could be used to treat the patients suffering from COVID-19 infection (
 <xref rid="ref30" ref-type="bibr">30</xref>). The patients affected with COVID-19 infection and who have no complications with the chloroquine drug are advised to take 500 mg of chloroquine two times a day for 10 days (
 <xref rid="ref31" ref-type="bibr">31</xref>). The ICMR recommends the use of hydroxychloroquine for high-risk COVID-19 cases (
 <xref rid="ref32" ref-type="bibr">32</xref>).
</p>
